• No results found

Search for novel genetic risk factors for venous thrombosis : a dual approach

N/A
N/A
Protected

Academic year: 2021

Share "Search for novel genetic risk factors for venous thrombosis : a dual approach"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Citation

Minkelen, R. van. (2008, February 18). Search for novel genetic risk factors for venous thrombosis : a dual approach. Retrieved from https://hdl.handle.net/1887/13501

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/13501

Note: To cite this publication please use the final published version (if applicable).

(2)

Search for novel genetic risk factors for venous thrombosis:

a dual approach

(3)
(4)

Search for novel genetic risk factors for venous thrombosis:

a dual approach

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnifi cus prof. mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op woensdag 18 februari 2009 klokke 16:15 uur

door

Rick van Minkelen

geboren te Rheden

in 1979

(5)

The research described in this thesis was fi nancially supported by the Netherlands Organization for Scientifi c Research (NWO, grant 912-02-036) and was performed at the Hemostasis and Thrombosis Research Center (now the Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis), Department of Hematology of the Leiden University Medical Center, Leiden, the Netherlands.

Financial support by the Netherlands Heart Foundation for the publication of this thesis is gratefully acknowledged.

Additional support was kindly provided by AstraZeneca B.V., Bayer Healthcare B.V., BD Biosciences, Greiner Bio-One B.V., Instrumentation Laboratory B.V., Promega Benelux B.V., Roche Diagnostics Nederland B.V., Sanquin, Siemens Healthcare Diagnostics B.V. and Snijders Scientifi c B.V..

Cover: Chromosomen in wol met bouwstenen (Lego®) Coverdesign and lay-out: Peggy van Minkelen

© 2009 R. van Minkelen ISBN: 978-90-6464-316-3

Printed by Ponsen & Looijen B.V., Wageningen, the Nethelands

(6)

Table of contents

Chapter 1 General introduction

Chapter 2 Candidate genes

2.1 Haplotypes of IL1B, IL1RN, IL1R1 and IL1R2 and the risk of venous thrombosis

2.2 Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction

2.3 Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis

2.4 The Marburg I polymorphism of factor seven-activating protease is not associated with venous thrombosis

Chapter 3 The Genetics In Familial Thrombosis (GIFT) Study

3.1 The Genetics In Familial Thrombosis (GIFT) study: sample collection and description of study population

3.2 Genome-wide scan in aff ected sibling pairs reveals two novel susceptibility regions for venous thromboembolism: the Genetics In Familial Thrombosis (GIFT) Study

3.3 Screening of eleven candidate genes, from the 7p21.3 and Xq25-q26.3 linkage regions, for association with venous thromboembolic risk:

results from The Genetics In Familial Thrombosis (GIFT) study

Chapter 4 General discussion and summary

Samenvatt ing Nawoord

Curriculum Vitae

Page 7

23 25 45

59 77

83 85 111

129

147

171 181 185

(7)

Referenties

GERELATEERDE DOCUMENTEN

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded.

The Genetics in Familial Thrombosis (GIFT) study was used in Chapter 3 in the search for novel genetic risk factors for venous thrombosis.. In the GIFT study we collaborated with

To test this hypothesis we genotyped eighteen single nucleotide polymorphisms (SNPs) in these genes, which together tag 25 haplotype groups, in all patients and control subjects of

We found that haplotype 3 (H3) of the gene (IL1RN) coding for the interleukin-1 receptor antagonist (IL-1Ra), the natural inhibitor of the proinfl ammatory cytokine IL-1,

When a novel sequence variation was found, we subsequently investigated the association of this variant with FIX levels and thrombotic risk in a large case-control study on the

Therefore we determined the Marburg I polymorphism in 471 consecutive patients with a fi rst episode of deep venous thrombosis (DVT) and 471 sex- and age-matched healthy controls

In about 40% of GIFT index patients none of the classical genetic risk factors (factor V Leiden, prothrombin 20210A, defi ciencies of protein C, S and antithrombin) was present

In total, 287 aff ected sibling pairs with an objectively confi rmed venous thromboembolism at young age (index patients ≤45 years) were included in the Genetics In Familial